The commonest clinical manifestations of MEN1 include parathyroid adenomas/hyperplasia resulting in primary hyperparathyroidism (in more than 90% of patients), NEN (more frequently within the pancreas, up to 70% of patients), and pituitary adenomas (in about 50% of cases) [9,10]. Here, MEN1 is linked to pituitary gland adenoma.